{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:48:01Z","timestamp":1792784881555,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Cancer Center Support Grant (CCSG) (PI: Dr. Peter Pisters) Lyda Hill Philanthropies","id":[{"id":"https:\/\/ror.org\/032sf2845","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"DOI":"10.1038\/s41375-026-03146-3","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:08:38Z","timestamp":1790852918000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ROR1 upregulation after CD19-CAR T-cell relapse in mantle cell lymphoma identifies a targetable vulnerability for ROR1-directed bispecific modalities"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8439-6043","authenticated-orcid":false,"given":"Yixin","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6231-5225","authenticated-orcid":false,"given":"Fangfang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"McIntosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7813-1292","authenticated-orcid":false,"given":"Heng-Huan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1910-8076","authenticated-orcid":false,"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-5486","authenticated-orcid":false,"given":"Michael","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"3146_CR1","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1182\/blood.2023021306","volume":"143","author":"A Minson","year":"2024","unstructured":"Minson A, Hamad N, Cheah CY, Tam C, Blombery P, Westerman D, et al. CAR T cells and time-limited ibrutinib as treatment for relapsed\/refractory mantle cell lymphoma: the phase 2 TARMAC study. Blood. 2024;143:673\u201384.","journal-title":"Blood"},{"key":"3146_CR2","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507\u201316.","journal-title":"N Engl J Med"},{"key":"3146_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/antib11010016","volume":"11","author":"R Tavarozzi","year":"2022","unstructured":"Tavarozzi R, Manzato E. The role of bispecific antibodies in non-Hodgkin\u2019s lymphoma: from structure to prospective clinical use. Antibodies. 2022;11:16.","journal-title":"Antibodies"},{"key":"3146_CR4","doi-asserted-by":"crossref","unstructured":"Castaneda-Puglianini O, Chavez JC. Bispecific antibodies for non-Hodgkin\u2019s lymphomas and multiple myeloma. Drugs Context. 2021;10:1\u201312.","DOI":"10.7573\/dic.2021-2-4"},{"key":"3146_CR5","doi-asserted-by":"publisher","first-page":"3190","DOI":"10.1182\/bloodadvances.2024013814","volume":"9","author":"P Diamanti","year":"2025","unstructured":"Diamanti P, Bailey BK, Iheanacho OE, Moppett JP, Nathwani AC, Blair A. Expression and treatment of ROR1+ cells with bispecific T-cell engagers in pediatric acute lymphoblastic leukemia. Blood Adv. 2025;9:3190\u2013201.","journal-title":"Blood Adv"},{"key":"3146_CR6","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1073\/pnas.1816262116","volume":"116","author":"S Zhang","year":"2019","unstructured":"Zhang S, Zhang H, Ghia EM, Huang J, Wu L, Zhang J, et al. Inhibition of chemotherapy-resistant breast cancer stem cells by a ROR1-specific antibody. Proc Natl Acad Sci USA 2019;116:1370\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3146_CR7","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1182\/blood.2021014760","volume":"140","author":"TJ Kipps","year":"2022","unstructured":"Kipps TJ. ROR1: an orphan becomes apparent. Blood. 2022;140:1583\u201391.","journal-title":"Blood"},{"key":"3146_CR8","first-page":"4759","volume":"11","author":"MP Long","year":"2018","unstructured":"Long MP, Wang HL, Luo YB, Yang JH. Targeting ROR1 inhibits epithelial-to-mesenchymal transition in human lung adenocarcinoma via mTOR signaling pathway. Int J Clin Exp Pathol. 2018;11:4759\u201370.","journal-title":"Int J Clin Exp Pathol"},{"key":"3146_CR9","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.stem.2018.05.018","volume":"22","author":"MY Choi","year":"2018","unstructured":"Choi MY, Widhopf GF 2nd, Ghia EM, Kidwell RL, Hasan MK, et al. Phase I trial: cirmtuzumab inhibits ROR1 signaling and stemness signatures in patients with chronic lymphocytic leukemia. Cell Stem Cell. 2018;22:951\u20139 e3.","journal-title":"Cell Stem Cell"},{"key":"3146_CR10","doi-asserted-by":"publisher","first-page":"17266","DOI":"10.1073\/pnas.1419599111","volume":"111","author":"S Zhang","year":"2014","unstructured":"Zhang S, Cui B, Lai H, Liu G, Ghia EM, Widhopf GF, et al. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy. Proc Natl Acad Sci USA 2014;111:17266\u201371.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3146_CR11","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1182\/bloodadvances.2017010215","volume":"1","author":"H Karvonen","year":"2017","unstructured":"Karvonen H, Chiron D, Niininen W, Ek S, Jerkeman M, Moradi E, et al. Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma. Blood Adv. 2017;1:2257\u201368.","journal-title":"Blood Adv"},{"key":"3146_CR12","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.4049\/jimmunol.1801327","volume":"203","author":"Q Zhang","year":"2019","unstructured":"Zhang Q, Wang HY, Liu X, Nunez-Cruz S, Jillab M, Melnikov O, et al. Cutting edge: ROR1\/CD19 receptor complex promotes growth of mantle cell lymphoma cells independently of the B cell receptor-BTK signaling pathway. J Immunol. 2019;203:2043\u20138.","journal-title":"J Immunol"},{"key":"3146_CR13","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.1182\/bloodadvances.2024015719","volume":"9","author":"E Shumilov","year":"2025","unstructured":"Shumilov E, Scholz JK, Seib M, Mazzeo P, Wurm-Kuczera R, Vucinic V, et al. Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed\/refractory large B-cell lymphoma. Blood Adv. 2025;9:3955\u201366.","journal-title":"Blood Adv"},{"key":"3146_CR14","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abj2820","volume":"8","author":"Z Bai","year":"2022","unstructured":"Bai Z, Woodhouse S, Zhao Z, Arya R, Govek K, Kim D, et al. Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL. Sci Adv. 2022;8:eabj2820.","journal-title":"Sci Adv"},{"key":"3146_CR15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s13045-021-01209-9","volume":"14","author":"J Lemoine","year":"2021","unstructured":"Lemoine J, Ruella M, Houot R. Born to survive: how cancer cells resist CAR T cell therapy. J Hematol Oncol. 2021;14:199.","journal-title":"J Hematol Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03146-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03146-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03146-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:23:32Z","timestamp":1790897012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03146-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":15,"alternative-id":["3146"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03146-3","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"assertion":[{"value":"9 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MW is consultant to AbbVie, Acerta Pharma, AstraZeneca, BeiGene, BioInvent, Deciphera, InnoCare, Janssen, Kite Pharma, Leukemia & Lymphoma Society, Lilly, Merck, Milken Institute, Oncternal, Parexel, Pepromene Bio, Pharmacyclics, and VelosBio, and he has received research support from Acerta Pharma, AstraZeneca, BeiGene, BioInvent, Celgene, Genmab, Genentech, Innocare, Janssen, Juno Therapeutics, Kite Pharma, Lilly, Loxo Oncology, Molecular Templates, Oncternal, Pharmacyclics, VelosBio, Vincerx. MW also received a speaker honorarium from AbbVie, Acerta Pharma, AstraZeneca, BeiGene, BioInvent, Dava Oncology, Eastern Virginia Medical School, IDEOlogy Health, Janssen, Kite Pharma, Leukemia & Lymphoma Society, LLC TS Oncology, Medscape, Meeting Minds Experts, MJH Life Sciences, Merck, Moffit Cancer Center, Oncology Specialty Group, OncLive, Pharmacyclics, Physicians Education Resources (PER), Practice Point Communications (PPC), and Studio ER Congressi. The remaining authors have no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The study was conducted in accordance with the principles of the Declaration of Helsinki and received ethical approval from the Institutional Review Board at The University of Texas MD Anderson Cancer Center.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}